KR940021579A - 골(骨)-관련 전사 조절인자형 단백질 및 이의 제조방법 - Google Patents

골(骨)-관련 전사 조절인자형 단백질 및 이의 제조방법 Download PDF

Info

Publication number
KR940021579A
KR940021579A KR1019940004507A KR19940004507A KR940021579A KR 940021579 A KR940021579 A KR 940021579A KR 1019940004507 A KR1019940004507 A KR 1019940004507A KR 19940004507 A KR19940004507 A KR 19940004507A KR 940021579 A KR940021579 A KR 940021579A
Authority
KR
South Korea
Prior art keywords
dna
protein
rna
recombinant protein
osf
Prior art date
Application number
KR1019940004507A
Other languages
English (en)
Inventor
마코토 오카자키
스나오 다케시타
신지 가와이
레이코 기쿠노
아만 에곤
Original Assignee
에이치. 가토
훽스트 저팬 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에이치. 가토, 훽스트 저팬 리미티드 filed Critical 에이치. 가토
Publication of KR940021579A publication Critical patent/KR940021579A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Obesity (AREA)

Abstract

마우스 및 사람을 포함한 포유동물의 골(骨)로부터 유도되는 OSF-6이라 불리우는 골-관련 단백질은, 골 형성에 중요한 역할을 수행할 수 있고 일 그룹의 전사 조절 인자에 속하는 새로운 천연형 포유동물 단백질이다.
OSF-6은 골에 대해 높은 기관 특이성을 나타낼 수 있으므로 골대사성 질환용 치료제 및 진단제로서 사용될 수 있다.

Description

골(骨)-관련 전사 조절인자형 단백질 및 이의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제 1 도는 마우스 OSF-6 단백질 구조의 도식도이다

Claims (11)

  1. 서열표의 서열번호 1에서 1번부터 442번까지의 아미노산 서열, 또는 이의 동족체 또는 이의 단편을 갖는 OSF-6을 포함하는 단백질.
  2. 제 1 항의 단백질을 암호화하는 DNA 또는 RNA.
  3. (a) (ⅰ) 외래 DNA를 갖는 세포에서 작용할 수 있는 전사 및 해독 조절 서열 및 (ⅱ) 상기 조절 서열에 연결된 재조합 단백질을 암호화하는 DNA 서열로 이루어진 외래 DNA를 갖는 세포 그룹을 제조하고, (b) 상기 세포 그룹을 재조합 단백질이 생성되는 조건하에서 배양하는 단계를 포함하며, 포유동물 OSF-6, 이의 동족체 또는 이의 단편인 재조합 단백질을 제조하는 방법.
  4. 제 3 항에 있어서, 조절 서열이 세포외로 재조합 단백질을 분비하기 위한 시그널 펩티아드를 암호화하는 DNA를 재조합 단백질을 암호화하는 DNA 서열의 상부에 바로 접하게 위치되도록 추가로 포함하는 방법.
  5. 제 3 항 또는 제 4 항에 있어서, 세포 그룹이 에스케리키아콜라이, 효모 또는 포유동물 세포인 방법.
  6. 제 2 항의 DNA 또는 RNA 전체 또는 이의 단편을 포함하는 진단 고안물.
  7. 제 1 항의 단백질을 포함하는 진단 고안물.
  8. 제 1 항의 단백질에 대한 폴리클로날 항체 및 모노클로날 항체.
  9. 제 8 항의 항체를 포함하는 진단 고안물.
  10. 제 1 항의 단백질을 포함하는 약제학적 제제.
  11. 엄격한 조건하에서 제 2 항의 DNA 또는 RNA에 하이브리드화하고 사람 OSF-6 유전자를 암호화하는 사람 DNA 또는 RNA.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940004507A 1993-03-10 1994-03-09 골(骨)-관련 전사 조절인자형 단백질 및 이의 제조방법 KR940021579A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP5048875A JPH06256210A (ja) 1993-03-10 1993-03-10 骨関連転写制御因子様タンパク質およびその製造法
JP93-48875 1993-03-10

Publications (1)

Publication Number Publication Date
KR940021579A true KR940021579A (ko) 1994-10-19

Family

ID=12815467

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940004507A KR940021579A (ko) 1993-03-10 1994-03-09 골(骨)-관련 전사 조절인자형 단백질 및 이의 제조방법

Country Status (6)

Country Link
US (1) US5578708A (ko)
EP (1) EP0614974A3 (ko)
JP (1) JPH06256210A (ko)
KR (1) KR940021579A (ko)
AU (1) AU5765594A (ko)
CA (1) CA2118642A1 (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074840A (en) 1994-02-18 2000-06-13 The Regents Of The University Of Michigan Recombinant production of latent TGF-beta binding protein-3 (LTBP-3)
DE4421536A1 (de) * 1994-06-20 1995-12-21 Hoechst Ag Perfluoralkylgruppen tragende phenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US6103491A (en) * 1995-07-26 2000-08-15 Creative Biomolecules, Inc. Methods and compositions for identifying morphogen analogs
US6090544A (en) * 1995-07-26 2000-07-18 Creative Biomolecules, Inc. Methods and compositions for identifying morphogen analogs
US7306903B1 (en) 1995-07-26 2007-12-11 Curis, Inc. Methods and compositions for identifying morphogen analogs
US5962224A (en) * 1995-12-19 1999-10-05 Dana-Farber Cancer Institute Isolated DNA encoding p62 polypeptides and uses therefor
US5928940A (en) * 1996-09-24 1999-07-27 Creative Biomolecules, Inc. Morphogen-responsive signal transducer and methods of use thereof
DE69840361D1 (de) 1997-07-30 2009-01-29 Univ Emory Neue knochenmineralisierungsproteine, dna, vektoren, expressionssysteme
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
US6364912B1 (en) 1999-09-17 2002-04-02 Depuy Orthopeaedics, Inc. Pleiotrophin-based compositions for enhancing connective tissue repair
JP2008500281A (ja) 2004-02-11 2008-01-10 アミリン・ファーマシューティカルズ，インコーポレイテッド アミリンファミリーペプチドおよびそれらを作成し使用するための方法
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
US8030016B2 (en) * 2006-07-31 2011-10-04 Teijin Pharma Limited Method for screening for vitamin D receptor ligands

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3472587B2 (ja) * 1992-08-28 2003-12-02 アベンティス ファーマ株式会社 骨関連カルボキシペプチダーゼ様タンパク質およびその製造法

Also Published As

Publication number Publication date
AU5765594A (en) 1994-09-15
EP0614974A3 (en) 1996-03-06
JPH06256210A (ja) 1994-09-13
EP0614974A2 (en) 1994-09-14
US5578708A (en) 1996-11-26
CA2118642A1 (en) 1994-09-11

Similar Documents

Publication Publication Date Title
US5885961A (en) Methods of using epithelins to modulate cell proliferation
CA2132954C (en) Modified ciliary neurotrophic factors
ES2206448T3 (es) Heregulinas (hrgs), proteinas de union de p185?erb2.
KR100393508B1 (ko) 인간 인터루킨 4의 안타고니스트 또는 부분적 아고니스트로서의 신규hIL-4 변이단백질
MD2311G2 (ro) Polipeptide de obezitate, fragment imunogen, analog, analog uman şi analog uman redus, moleculă de acid nucleic izolată, moleculă de ADN, moleculă de acid nucleic marcată detectabil, vectori conţinând molecula ADN, anticorp monoclonal, anticorp policlonal şi compoziţie farmaceutică pentru reducerea greutăţii corporale a animalelor
KR840008026A (ko) 인형 베타 신경 생장인자 호르몬, 이것의 표현 벡터와 dna서열 및 제조방법
KR940021579A (ko) 골(骨)-관련 전사 조절인자형 단백질 및 이의 제조방법
KR920004572A (ko) 재조합 진드기 알레르겐
EP0471011A1 (en) HUMAN LACTOFERRIN cDNA SEQUENCE.
DE69637874D1 (de) C-C CHEMOKIN REZEPTOR 3: CKR-3 ODER Eos-L2
BR0110090A (pt) Proteìna, processos para hidrolisar ligações beta-glucosìdicas e beta-xilosìdicas e para produzir um polipeptìdeo, sequência de ácido nucleico, construção de ácido nucleico, cepa microbiana recombinante, e, sonda de oligonucleotìdeo
KR970002917B1 (ko) 인터루킨-i 억제제
Chen Vitellogenin in locusts (Locusta migratoria): translation of vitellogenin mRNA in Xenopus oocytes and analysis of the polypeptide products
Davis et al. Basic fibroblast growth factor induces 3T3 fibroblasts to synthesize and secrete a cyclophilin-like protein and β2-microglobulin
Suran et al. N-terminal sequences of heavy and light chains of leopard shark immunoglobulins: evolutionary implications.
CA2092768A1 (en) Protein with bone formation ability and process for its production
Negro et al. Synthesis, purification, and characterization of human ciliary neuronotrophic factor from E. coli
Plakidou-Dymock et al. Calreticulin—a stress protein induced in the renal epithelial cell line NBL-1 by amino acid deprivation
Razis et al. The periplasmic expression of recombinant human epidermal growth factor (hEGF) in Escherichia coli
US5474913A (en) Process for the preparation of motilin-like polypeptide and expression thereof
DE69925271T2 (de) Angiostatin-bindendes protein
Margolis et al. Molecular biological approaches to the olfactory system: olfactory marker protein as a model
Tanaka et al. Heterogeneity of the principal sigma factor in Escherichia coli: The rpoS gene product, sigma super (38), is a second principal sigma factor of RNA polymerase in stationary-phase Escherichia coli.
NO178504C (no) Fr.måte for fr.stilling av minaktivin,DNA-molekyl,gen,vert,prober,preparat som omfatter prober,reagens for lokalisering og defini. av grenser for tumor i histologiske pröver,samt anvendelse av DNA-molekyl,minaktivin og preparat
JP3165833B2 (ja) 神経突起伸長活性を有する蛋白質

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid